View More Recent Stories
-
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute
-
NRx Pharmaceuticals (NRXP) Files Patent Application for NRX-100
-
NRx Pharmaceuticals (NRXP) and HOPE Sign Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
-
BTIG Starts NRx Pharmaceuticals, Inc. (NRXP) at Buy
-
NRx Pharmaceuticals (NRXP) and HOPE Announce Definitive Purchase Agreement with Dura Medical
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics Sign LoI with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics Execute Agreement for $27M Funding Transaction for HOPE Clinic Acquisition
-
NRx Pharmaceuticals (NRXP) Advances Relationship with Anson Funds with $8.9M Financing
-
NRx Pharmaceuticals (NRXP) Regains Nasdaq Compliance
-
NRx Pharmaceuticals (NRXP) Appoints Michael Taylor to its Board, Anita Nunes as Board Observer
-
NRx Pharmaceuticals (NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
NRx Pharmaceuticals (NRXP) Appoints Michael Abrams as Chief Financial Officer
-
NRx Pharmaceuticals (NRXP) Reschedules Q3 Call
-
NRx Pharmaceuticals' (NRXP) HOPE Therapeutics Announce Signing of a LoI to Acquire its First Florida Interventional Psychiatry Clinics
-
EF Hutton Starts NRx Pharmaceuticals, Inc. (NRXP) at Buy
-
NRx Pharmaceuticals (NRXP) and HOPE Therapeutics to Acquire a Premier West Coast Interventional Psychiatric Clinic
-
NRx Pharmaceuticals (NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100
-
HOPE Therapeutics and NRx Pharmaceuticals (NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
-
NRx Pharmaceuticals (NRXP) Announces CEO Resignation
-
NRx Pharmaceuticals (NRXP) Announces Up to $16M Secured Debt Financing from Anson Funds
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NRXP) Announce Alignment with FDA on Pediatric Study Plan for NRX-100
-
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NRXP) Announce Arbitration Order Enabling HOPE Therapeutics Spinoff
-
NRx Pharmaceuticals (NRXP) Issues Shareholder Letter
-
NRx Pharmaceuticals (NRXP) to Proceed with Two New Drug Applications in 2024, NRX-101 Returned to the Company for Filing
-
NRx Pharmaceuticals (NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
-
NRx Pharmaceuticals (NRXP) Issues Shareholder Update Letter

